| A Nurse-led Individualized Educational Intervention (NCT03127462) | Lina R. Khoury | 2017-05-01 |
| A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (NCT03090100) | Janssen Research & Development, LLC | 2017-04-27 |
| Vascular Inflammation in Psoriasis - Apremilast (NCT03082729) | University of Pennsylvania | 2017-04-24 |
| Role of Chemokine and Chemokine Receptor in Psoriasis (NCT03302390) | University of California, Davis | 2017-04-17 |
| A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris (NCT03073213) | Eli Lilly and Company | 2017-04-13 |
| A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium (NCT03097003) | Amgen | 2017-04-06 |
| Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab (NCT03099083) | AbbVie | 2017-03-31 |
| The Norwegian Drug Monitoring Study (NCT03074656) | Diakonhjemmet Hospital | 2017-03-01 |
| Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (NCT02905331) | Janssen Research & Development, LLC | 2017-02-28 |
| A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (NCT03047395) | AbbVie | 2017-02-27 |
| A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis (NCT03062618) | PRCL Research Inc. | 2017-02-20 |
| Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact (NCT02999698) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2017-02-01 |
| Evaluating Treatment Resistant Dermatitis TaroIIR (NCT03050294) | Wake Forest University Health Sciences | 2017-02-01 |
| A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (NCT03022045) | AbbVie | 2017-01-26 |
| Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants (NCT03004768) | Bristol-Myers Squibb | 2017-01-26 |
| APremilast After FumaRic Acid Ester Treatment (NCT02954081) | Amgen | 2017-01-26 |
| Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (NCT02829424) | Assistance Publique Hopitaux De Marseille | 2017-01-23 |
| Molecular Signatures in Inflammatory Skin Disease (NCT03358693) | Prof. Dr. Stephan Weidinger | 2017-01-20 |
| Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) (NCT03253666) | Harvard School of Public Health (HSPH) | 2017-01-01 |
| Estimation of Level of ERAP1 Expression in Lesional and Non Lesional Skin of Psoraitic Patients and Healthy Controls. (NCT03767114) | Kasr El Aini Hospital | 2017-01-01 |
| A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis (NCT03022617) | University of Alabama at Birmingham | 2017-01-01 |
| A Study of Ixekizumab in Participants With Plaque Psoriasis (NCT02993471) | Eli Lilly and Company | 2016-12-22 |
| Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis (NCT02978690) | Boehringer Ingelheim | 2016-12-19 |
| Study of Secukinumab With 2 mL Pre-filled Syringes (NCT02748863) | Novartis Pharmaceuticals | 2016-12-12 |
| A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT02951533) | Janssen-Cilag G.m.b.H | 2016-12-12 |
| An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis (NCT02872285) | Lycera Corp. | 2016-12-05 |
| BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT03000075) | AbbVie | 2016-12-02 |
| Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects (NCT03018509) | Akros Pharma Inc. | 2016-12-01 |
| Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects (NCT03007810) | Tianjin Hemay Bio-Tech Co., Ltd | 2016-12-01 |
| Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis (NCT03180866) | Illumicure Inc | 2016-12-01 |
| Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis (NCT02931838) | Bristol-Myers Squibb | 2016-11-15 |
| A Study of LY3041658 in Participants With Skin Diseases (NCT02896868) | Eli Lilly and Company | 2016-11-08 |
| Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis (NCT04459780) | Pierre Fabre Dermo Cosmetique | 2016-10-25 |
| BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study (NCT02936492) | Bayer | 2016-10-24 |
| Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis (NCT03475914) | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2016-10-13 |
| BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test (NCT02940002) | Bayer | 2016-10-12 |
| Immunologic Response to Secukinumab in Plaque Psoriasis (NCT02592018) | University of California, San Francisco | 2016-10-01 |
| Psychotherapy for Patients With Psoriasis: Effects in Quality of Life (NCT02944630) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2016-10-01 |
| Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis (NCT02801435) | Betta Pharmaceuticals Co., Ltd. | 2016-09-17 |
| This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis (NCT02772601) | AbbVie | 2016-09-15 |
| Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments (NCT03051347) | Northwestern University | 2016-09-01 |
| Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray (NCT02985736) | Psoriasis Treatment Center of Central New Jersey | 2016-09-01 |
| Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008 (NCT02955693) | Almirall, S.A. | 2016-09-01 |
| Microneedle Patch for Psoriatic Plaques (NCT02955576) | The Catholic University of Korea | 2016-09-01 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (NCT02776033) | GlaxoSmithKline | 2016-08-30 |
| A Study of SHR-1314 in Healthy Subjects (NCT02934412) | Atridia Pty Ltd. | 2016-08-22 |
| Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT02850965) | Boehringer Ingelheim | 2016-08-17 |
| The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis (NCT02622386) | University of Michigan | 2016-08-11 |
| BE Study in Patients - Methotrexate Tablets (NCT02940561) | Amneal Pharmaceuticals, LLC | 2016-08-01 |
| Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (NCT02933528) | Sun Pharmaceutical Industries, Inc. | 2016-07-11 |
| Single Cell Genomics of Psoriatic Skin (NCT02929745) | University of California, San Francisco | 2016-07-01 |
| A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice (NCT02740218) | Amgen | 2016-06-30 |
| Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis (NCT02785185) | Bausch Health Americas, Inc. | 2016-06-01 |
| International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis (NCT02762994) | Biocad | 2016-06-01 |
| Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy (NCT02408159) | Innovaderm Research Inc. | 2016-06-01 |
| Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population (NCT02795416) | Novartis Pharmaceuticals | 2016-06-01 |
| Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis (NCT02763969) | Bristol-Myers Squibb | 2016-05-18 |
| Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) (NCT02538341) | University of Alabama at Birmingham | 2016-05-01 |
| Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients (NCT02908347) | MetrioPharm AG | 2016-05-01 |
| Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis (NCT02796014) | Istanbul Medeniyet University | 2016-05-01 |
| Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) (NCT02750800) | AbbVie | 2016-04-07 |
| Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis (NCT02785172) | Bausch Health Americas, Inc. | 2016-04-01 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (NCT02718898) | Eli Lilly and Company | 2016-04-01 |
| Oral Psoriasis Treatment Adherence and Intervention Study (NCT02850900) | Wake Forest University Health Sciences | 2016-04-01 |
| Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis (NCT02917434) | Vastra Gotaland Region | 2016-04-01 |
| A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests (NCT03406117) | Haus Bioceuticals | 2016-04-01 |
| Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis (NCT02630901) | Prothena Biosciences Limited | 2016-03-17 |
| BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT02694523) | AbbVie | 2016-03-01 |
| Topical Psoriasis Study for Patients Receiving Biologic Therapy (NCT02983981) | Psoriasis Treatment Center of Central New Jersey | 2016-03-01 |
| Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity (NCT02602925) | Radboud University Medical Center | 2016-03-01 |
| BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT02684357) | AbbVie | 2016-03-01 |
| Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis (NCT02752672) | Medical University of Graz | 2016-03-01 |
| Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis (NCT03848806) | Haus Bioceuticals | 2016-02-29 |
| BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment (NCT02672852) | AbbVie | 2016-02-29 |
| Observational Study of Apremilast in Patients With Psoriasis in The Netherlands (NCT02652494) | Amgen | 2016-02-22 |
| MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (NCT02660580) | Fresenius Kabi SwissBioSim GmbH | 2016-02-16 |
| Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis (NCT02652065) | Hospices Civils de Lyon | 2016-02-08 |
| Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis (NCT02785159) | Bausch Health Americas, Inc. | 2016-02-01 |
| BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT02684370) | AbbVie | 2016-02-01 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035 (NCT02690142) | Affibody | 2016-02-01 |
| A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis (NCT02618616) | Ziarco Pharma Ltd | 2016-01-11 |
| Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis (NCT02294981) | University of California, San Francisco | 2016-01-01 |
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis (NCT02644954) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2016-01-01 |
| Proton Pump Inhibitors Use in Patients With Psoriasis (NCT02624544) | EMS | 2016-01-01 |
| A Registry of Patients With Moderate to Severe Plaque Psoriasis (NCT02786186) | Novartis Pharmaceuticals | 2015-12-23 |
| A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (NCT02635204) | Promius Pharma, LLC | 2015-12-01 |
| Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients (NCT02574091) | Betta Pharmaceuticals Co., Ltd. | 2015-11-26 |
| A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis (NCT02564042) | GlaxoSmithKline | 2015-11-23 |
| KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis (NCT05522816) | PharmaEssentia | 2015-10-27 |
| Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis (NCT02548052) | GlaxoSmithKline | 2015-10-22 |
| A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis (NCT02576678) | Amgen | 2015-10-13 |
| Cross Sectional Analysis of Healthcare for Psoriasis in 4 European Countries (NCT02668341) | Universitätsklinikum Hamburg-Eppendorf | 2015-10-01 |
| An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis (NCT02407041) | Galectin Therapeutics Inc. | 2015-09-01 |
| Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis (NCT02572700) | Frederiksberg University Hospital | 2015-09-01 |
| Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis (NCT02581345) | Momenta Pharmaceuticals, Inc. | 2015-09-01 |
| Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment (NCT03440541) | Egyptian Atomic Energy Authority | 2015-08-04 |
| A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (NCT02626793) | Amgen | 2015-08-03 |
| An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers (NCT03724292) | Vitae Pharmaceuticals Inc., an Allergan affiliate | 2015-08-01 |
| An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) (NCT02451839) | AbbVie | 2015-07-06 |
| Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome (NCT02550080) | Shandong Provincial Institute of Dermatology and Venereology | 2015-07-01 |